Drug Trial Radar · NCT02477449
Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 2015
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- Lee's Pharmaceutical LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- CVie Therapeutics Co. Ltd.
- First posted
- Jun 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1 study to investigate safety of istaroxime in healthy chinese volunteers.
Conditions
- Healthy
Interventions
istaroximeDrug
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
9% Saline (NS)Drug
infusion for 24 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- safety of istaroxime in healthy volunteers is measured by varition of heart functon, blood pressure and heart ratioTime frame: one week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The 307th hospital of chinese People's liberation army
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.